Community Contributor
Member since 2025
Views
20.4k Total number of views
Fair Values Set
277 Total number of fair values set
Comments
3 Total number of comments
Followers
1 Total number of followers

No bio added yet

No link added
US$234.75
12.8% overvalued intrinsic discount
Fair Value
Revenue
13.6% p.a.
Profit Margin
10.54%
Future PE
31.96x
Price in 2028
US$295.73
US$73.83
19.1% undervalued intrinsic discount
Fair Value
Revenue
14.51% p.a.
Profit Margin
4.33%
Future PE
18.91x
Price in 2028
US$97.27
US$228.21
73.9% overvalued intrinsic discount
Fair Value
Revenue
5.16% p.a.
Profit Margin
32.4%
Future PE
25x
Price in 2028
US$291.48
PLX logo
Protalix BioTherapeutics

Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth

As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%.Read more

View narrative
US$4.23
54.8% undervalued intrinsic discount
Fair Value
Revenue
14% p.a.
Profit Margin
20%
Future PE
29.15x
Price in 2028
US$5.11
US$152.71
64.1% undervalued intrinsic discount
Fair Value
Revenue
30.8% p.a.
Profit Margin
10%
Future PE
25x
Price in 2030
US$224.38
US$40.73
60.2% undervalued intrinsic discount
Fair Value
Revenue
6.22% p.a.
Profit Margin
11.11%
Future PE
10x
Price in 2028
US$51.3
US$37.42
123.3% overvalued intrinsic discount
Fair Value
Revenue
26.99% p.a.
Profit Margin
49%
Future PE
20x
Price in 2030
US$58.69